Impact of covid-19 on Healthcare contract research outsourcing market
According to a new report published by Transparency Market Research (TMR) titled “Healthcare Contract Research Outsourcing Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025,” the global healthcare contract research outsourcing market was valued at US$ 30.0 billion in 2016 and is expected to grow at a CAGR of 6.8% from 2017 to 2025. Due to an increase in demand for cost optimization with shorter drug development schedules and globalization of clinical trials, North America and Europe are expected to lead the global market. The leading participants in the healthcare contract research outsourcing market are developing strategic solutions for long-term partnerships with healthcare businesses at various phases of drug development, lowering total development costs and enhancing the cost effectiveness and efficiency of the process. Commercial expansion is a priority for businesses. In Latin America, the market for healthcare contract research outsourcing is expected to increase at a moderate rate.
Complex Regulatory and Growing Regulatory Burden to Fuel Market Growth
The increased complexity of regulatory procedures and increased involvement of healthcare providers in the drug approval and reimbursement process are expected to drive the worldwide healthcare contract research outsourcing market. Healthcare contract research outsourcing is being fueled by CROs’ therapeutic competence and diverse regional filing process knowledge. Contract research firms offer a variety of services and solutions to help with regulatory filing at different phases of the drug development process. These services and business solutions provided by CROs assist healthcare organizations in rapidly and effectively completing simultaneous regulatory submissions in many areas. The leading participants in the healthcare contract research outsourcing market are developing strategic solutions for long-term partnerships with healthcare businesses at various phases of drug development, lowering total development costs and enhancing the cost effectiveness and efficiency of the process. Commercial expansion is a priority for businesses.
Comments
Post a Comment